Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518895 · ClinicalTrials.gov registry record · Phase 3
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
A Phase 3 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00518895: Completed Phase 3 study, sponsored by Genta Incorporated.
NCT00518895 is a Phase 3 study that has completed, run by Genta Incorporated. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00518895, a Phase 3 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This study is being performed to prospectively determine whether dacarbazine plus Genasense is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit of normal). LDH is a biomarker strongly associated with improved outcomes in a recent trial of dacarbazine plus Genasense.
Interventions
- DRUG dacarbazine plus Genasense
- DRUG dacarbazine plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00518895 record still lists
NCT00518895 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which dacarbazine plus Genasense is the first listed.
NCT00518895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00518895 about?
NCT00518895 is a clinical study titled "Trial of Dacarbazine With or Without Genasense in Advanced Melanoma". This study is being performed to prospectively determine whether dacarbazine plus Genasense is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit of normal). LDH is a bioma...
What is the current status of trial NCT00518895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2007-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00518895?
The interventions under investigation include: dacarbazine plus Genasense (DRUG), dacarbazine plus placebo (DRUG).
Who is sponsoring clinical trial NCT00518895?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00518895's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia